{"schema_version":"secwatch.filing_event.v1","accession":"0000318154-25-000054","form_type":"8-K","ticker":"AMGN","cik":"0000318154","company_name":"AMGEN INC","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.040033+00:00","generated_at":"2026-05-17T21:08:01.710836+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Amgen Q2 revenue $9.2B (+9% YoY); GAAP EPS $2.65 (+92%), non-GAAP EPS $6.02 (+21%)","bullets":["Total revenues $9.2B, up 9% YoY; product sales up 9% on 13% volume growth, partially offset by 3% lower net selling price.","GAAP EPS $2.65 vs $1.38 (+92%); GAAP operating income $2.7B, margin 30.3%.","Non-GAAP EPS $6.02 vs $4.97 (+21%); non-GAAP operating margin 48.9%.","Free cash flow $1.9B in Q2, down from $2.2B, reflecting deferred 2024 tax payments and higher capex.","Fifteen products had double-digit sales growth, including Repatha, EVENITY, IMDELLTRA, BLINCYTO, TEZSPIRE, UPLIZNA, TAVNEOS."],"urls":{"canonical":"https://secwatch.observer/filing/0000318154-25-000054","json":"https://secwatch.observer/filing/0000318154-25-000054.json","markdown":"https://secwatch.observer/filing/0000318154-25-000054.md","text":"https://secwatch.observer/filing/0000318154-25-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318154/000031815425000054/0000318154-25-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318154/000031815425000054/amgn-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:08:01.710836+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}